Systemic Sclerosis: From Pathogenesis Towards Targeted Immunotherapies

Author(s): Lazaros I. Sakkas, Ian C. Chikanza, Chris D. Platsoucas

Journal Name: Current Rheumatology Reviews

Volume 8 , Issue 1 , 2012

Become EABM
Become Reviewer
Call for Editor


Systemic sclerosis (SSc), a chronic disease with widespread collagen deposition, has three pathogenetic facets: immune activation, microvasculopathy and fibroblast activation. Immune activation and microvasculopathy occur very early in the disease process, and inflammatory infiltrates in the skin are restricted in early-phase disease. There is good evidence that fibroblast activation with collagen production may be triggered by the immune system. In early-phase disease, we slowly move from general immunosuppression to therapeutically targeting specific molecules involved in immune activation, such as T cell-directed targets, B cell-directed targets, cytokine targets, and tyrosine kinases targets.

Keywords: B cell, fibroblast, immune activation, immunotherapy, systemic sclerosis, targeted therapy, T cell

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Published on: 25 June, 2012
Page: [45 - 55]
Pages: 11
DOI: 10.2174/157339712801318920

Article Metrics

PDF: 28